Publications: Dr Ozlem Yildiz

Yildiz O, Schroth J, Tree T, Turner MR, Shaw PJ, Henson SM, Malaspina A ( 2022 ) . Senescent-like Blood Lymphocytes and Disease Progression in Amyotrophic Lateral Sclerosis . Neurology Neuroimmunology & Neuroinflammation vol. 10 , ( 1 )

Allen-Philbey K, Trane SD, Yildiz O, Adams A, Turner B, Marta M, Mathews J, Altmann D et al. ( 2022 ) . Personalised immunotherapy in active multiple sclerosis using injectable cladrib- ine: Follow-up of the BartsMS cohort . Journal of Neurology Neurosurgery & Psychiatry vol. 93 , ( 6 ) a2.3 - a2a2 .

Yildiz O, Schroth J, Lombardi V, Pucino V, Bobeva Y, Yip PK, Schmierer K, Mauro C et al. ( 2022 ) . The Expression of Active CD11b Monocytes in Blood and Disease Progression in Amyotrophic Lateral Sclerosis . International Journal of Molecular Sciences vol. 23 , ( 6 )

Thompson AG, Gray E, Verber N, Bobeva Y, Lombardi V, Shepheard SR, Yildiz O, Feneberg E et al. ( 2022 ) . Multicentre appraisal of amyotrophic lateral sclerosis biofluid biomarkers shows primacy of blood neurofilament light chain . Brain Communications vol. 4 , ( 1 )

Allen-Philbey K, De Trane S, Mao Z, Álvarez-González C, Mathews J, MacDougall A, Stennett A, Zhou X et al. ( 2021 ) . Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients . Therapeutic Advances in Neurological Disorders vol. 14 ,

Puentes F, Lombardi V, Lu C, Yildiz O, Fratta P, Isaacs A, Bobeva Y, Wuu J et al. ( 2021 ) . Humoral response to neurofilaments and dipeptide repeats in ALS progression . Annals of Clinical and Translational Neurology vol. 8 , ( 9 ) 1831 - 1844 .

Allen-Philbey K, De Trane S, Stennett A, Yildiz O, Adams A, Turner B, Marta M, Gnanapavan S et al. ( 2021 ) . Cladribine personalised dosing for active multiple sclerosis: BartsMS cohort follow-up (2528) . Neurology vol. 96 , ( 15_supplement )

Allen-Philbey K, De Trane S, Stennett A, Yildiz O, Adams A, Turner B, Marta M, Gnanapavan S et al. ( 2021 ) . Cladribine Personalised Dosing to Treat Active Multiple Sclerosis - Follow-up in 250 patients . MULTIPLE SCLEROSIS JOURNAL . vol. 27 , 90 - 91 .

Allen-Philbey K, De Trane S, Stennett A, Yildiz O, Adams A, Turner B, Marta M, Gnanapavan S et al. ( 2021 ) . Cladribine personalised dosing for active multiple sclerosis: BartsMS cohort follow-up . NEUROLOGY . vol. 96 ,

Allen-Philbey K, De Trane S, Stennett A, Yildiz O, Adams A, Turner B, Marta M, Gnanapavan S et al. ( 2021 ) . Up to 6 years follow-up of people with MS (n=250) receiving cladribine . MULTIPLE SCLEROSIS JOURNAL . vol. 27 , 546 - 547 .

Mateo-Casas M, Reyes S, O'Toole EA, De Trane S, Yildiz O, Allen-Philbey K, Mathews J, Baker D et al. ( 2020 ) . Severe skin reactions associated with cladribine in people with multiple sclerosis . Multiple Sclerosis and Related Disorders . vol. 43 ,

Reyes S, Suarez S, Allen-Philbey K, Yildiz Ö, Mathews J, Anjorin G, Edwards F, Jain C et al. ( 2020 ) . Socioeconomic status and disease-modifying therapy prescribing patterns in people with multiple sclerosis . Multiple Sclerosis and Related Disorders vol. 41 ,

Allen-Philbey K, De Trane S, Stennett A, Yildiz O, Adams A, Turner B, Marta M, Gnanapavan S et al. ( 2020 ) . Cladribine personalised dosing to treat multiple sclerosis: observations in 208 patients . MULTIPLE SCLEROSIS JOURNAL . vol. 26 , 522 - 523 .

Reyes S, Allen-Philbey K, Suarez S, Yildiz Ö, Turner B, Gnanapavan S, Schmierer K, Marta M et al. ( 2019 ) . 192 Does socioeconomic status impact on the prescription of disease-modifying treatments in people with multiple sclerosis? . Journal of Neurology Neurosurgery & Psychiatry . vol. 90 ,

De Trane S, Mao Z, Alvarez-Gonzalez C, Allen-Philbey K, Yildiz O, Campion T, Adams A, Turner B et al. ( 2019 ) . Cladribine to treat Relapsing and Progressive Multiple Sclerosis - experience in >200 patients (S26.008) . Neurology vol. 92 , ( 15_supplement )

Mateo-Casas M, Reyes S, De Trane S, Yildiz O, Turner B, Mathews J, Giovannoni G, O’toole E et al. ( 2019 ) . Severe skin reactions associated with Cladribine treatment in patients with multiple sclerosis (P4.2-022) . Neurology vol. 92 , ( 15_supplement )

De Trane S, Allen-Philbey K, Stennett A, Yildiz O, Adams A, Turner B, Marta M, Gnanapavan S et al. ( 2019 ) . Cladribine at all stages of MS: two-year follow-up in 154 patients . MULTIPLE SCLEROSIS JOURNAL . vol. 25 , 519 - 520 .

De Trane S, Mao Z, Alvarez-Gonzalez C, Allen-Philbey K, Yildiz O, Campion T, Adams A, Turner B et al. ( 2019 ) . Cladribine to treat Relapsing and Progressive Multiple Sclerosis - experience in >200 patients . NEUROLOGY . vol. 92 ,

Zubiri I, Lombardi V, Bremang M, Mitra V, Nardo G, Adiutori R, Lu C-H, Leoni E et al. ( 2018 ) . Tissue-enhanced plasma proteomic analysis for disease stratification in amyotrophic lateral sclerosis . Molecular Neurodegeneration vol. 13 , ( 1 )

Mao Z, Álvarez-González C, Allen-Philbey K, De Trane S, Yildiz O, Campion T, Adams A, Turner BP et al. ( 2018 ) . Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies . Multiple Sclerosis and Related Disorders vol. 27 , 247 - 253 .

Mao Z, Álvarez-Gonzalez C, De Trane S, Yildiz O, Albor C, Doctor G, Soon D, Pepper G et al. ( 2018 ) . Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings? . Multiple Sclerosis Journal - Experimental, Translational and Clinical vol. 4 , ( 2 ) 2055217318783767 - 2055217318783767 .

Yildiz O, Mao Z, Adams A, Dubuisson N, Allen-Philbey K, Giovannoni G, Malaspina A, Baker D et al. ( 2018 ) . Disease activity in progressive multiple sclerosis can be effectively reduced by cladribine . Multiple Sclerosis and Related Disorders vol. 24 , 20 - 27 .

Mao Z, Alvarez-Gonzalez C, Yildiz O, Allen-Philbey K, Turner B, Gnananpavan S, Marta M, Mathews J et al. ( 2018 ) . Personalised dosing of cladribine for people with multiple sclerosis (P3.400) . Neurology . vol. 90 ,

Reyes S, Allen-Philbey K, Suarez S, Yildiz Ö, Turner B, Gnanapavan S, Schmierer K, Marta M et al. ( 2018 ) . The Impact of Socioeconomic Status on Treatment Choice in Patients with Multiple Sclerosis. (P2.346) . Neurology . vol. 90 ,

De Trane S, Mao Z, Alvarez-Gonzalez C, Allen-Philbey K, Yildiz O, Campion T, Adams A, Turner BP et al. ( 2018 ) . Cladribine personalised dosing in people with MS (n>200) - four years experience in clinical care .

Yildiz O, Mao Z, Adams A, Dubuisson N, Allen-Philbey K, Giovannoni G, Malaspina A, Baker D et al. ( 2018 ) . Elevated neurofilament light chain levels in progressive multiple sclerosis effectively reduced by cladribine treatment . MULTIPLE SCLEROSIS JOURNAL . vol. 24 , 949 - 949 .

Allen-Philbey K, Yildiz O, Raciborska D, Stennett A, Mathews J, Turner B, Giovannoni G, Schmierer K ( 2018 ) . Systematic multidimensional clinical point-of-care monitoring of people with multiple sclerosis using 3test . MULTIPLE SCLEROSIS JOURNAL . vol. 24 , 569 - 569 .